Dr. Reddy's Laboratories Limited (RDY) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Dr. Reddy's Laboratories ... (RDY)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

15.28

-0.03 (-0.20%)

At close: Jan 14, 2025, 3:59 PM

undefined% (undefined)

Bid	15.13
Market Cap	12.73B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.77
PE Ratio (ttm)	19.84
Forward PE	n/a
Analyst	Buy

Ask	15.29
Volume	844,220
Avg. Volume (20D)	1,290,755
Open	15.31
Previous Close	15.31
Day's Range	15.15 - 15.35
52-Week Range	13.43 - 16.89
Beta	undefined

About RDY

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finish...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Apr 11, 2001

Employees 27,048

Stock Exchange NYSE

Ticker Symbol RDY

Website https://www.drreddys.com

Analyst Forecast

According to 1 analyst ratings, the average rating for RDY stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 11.26% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Dr. Reddy's Laboratories Limited is scheduled to release its earnings on Jan 23, 2025, before market opens.
Analysts project revenue of $964.48M, reflecting a 11.24% YoY growth and earnings per share of 0.19, making a -5.00% decrease YoY.

Why Price Moved

6 months ago · Source

+4.65%

Dr. Reddy's Laboratories shares are trading higher... Unlock content with Pro Subscription

8 months ago · Source

-4.74%

Dr Reddy's Laboratories shares are trading lower following a Q4 revenue miss.

News

1 month ago · zacks.com

3 Emerging Market Stocks to Buy as 2024 Wraps Up

Here, we have picked three emerging market stocks, QFIN, YTRA and RDY, which are expected to show robust growth in 2025 on their growth strategies and fundamentals.

1 month ago · zacks.com

Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio

RDY enjoys a strong foothold in the global generics market due to its deep generic drugs pipeline. Its efforts to strengthen its biosimilars portfolio are commendable.

1 month ago · zacks.com

RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma

Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma.

1 month ago · businesswire.com

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. announced the launch of Toripalimab in India.

1 month ago · businesswire.com

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg in the U.S. market.

2 months ago · zacks.com

Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow

RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time acquisition cost and impairment charge on non-current assets.

2 months ago · seekingalpha.com

Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Company Participants Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financia...

2 months ago · businesswire.com

Dr. Reddy's Q2 & H1FY25 Financial Results

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and half year ended September 30, 2024.

2 months ago · businesswire.com

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanAssociationfortheAdvancementofScience--Dr. Reddy's has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Su...